Cisterna Biologics · Mar 2026
Official company update describing successful completion of an NSF SBIR Phase I project demonstrating yeast-engineered mRNA purification and function in human cells.
High quality mRNA for therapeutic application
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Cisterna Biologics is a Carlsbad, California biotech founded in 2022 that provides high-purity RNA products for research, diagnostics, and therapeutics. Its platform centers on custom RNA synthesis and an mRNA-focused purification system designed to reduce dsRNA, truncated RNA, and other contaminants.
Primary product
High-purity custom RNA and mRNA synthesis, including the SPECC mRNA platform
Founded
2022
Headquarters
Carlsbad, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
RNA therapeutics / mRNA synthesis
Offices
0 jobs at Cisterna Biologics
Check back later for new openings
Business model
Stage
seed
Total raised
$625K
Latest round
Seed Round · Dec 2022
Latest amount
$125K
Dec 2022
Sep 2022 · Y Combinator
Leadership
Founder and CEO
Public materials present a science-first, researcher-focused culture centered on RNA purity, practical technical resources, and faster paths to high-quality RNA for biotech and academic users.
Pricing
Mixed model: quote-based custom synthesis plus fixed-price catalog SKUs; order flow supports quote requests, purchase orders, and Net30 invoicing.
Differentiators
Technology
Customers
Estimated revenue
Less than $0.5M
Estimated monthly visits
969
Traffic estimate as of Aug 2024
Cisterna Biologics · Mar 2026
Official company update describing successful completion of an NSF SBIR Phase I project demonstrating yeast-engineered mRNA purification and function in human cells.
LinkedIn / Cisterna Biologics · Jul 2025
Company post announcing non-dilutive NIH NCATS SBIR Phase I support for SPECC platform development and validation.
LinkedIn / Cisterna Biologics · Jun 2025
Company post announcing NIH NIGMS STTR Phase I support to develop novel polymerases for high-quality RNA production with UT-Austin collaboration.
NIH RePORTER · Jun 2025
NIH project page documents a $350,000 award for Cisterna Biologics to develop psychrophilic RNA polymerases and SPECC-based purification to improve mRNA purity.
SBIR.gov · Aug 2024
NSF award page shows a $274,980 Phase I project to develop yeast-based mRNA production and purification.